Recombinant antibodies for cancer therapy

Expert Opinion on Biological Therapy

Volumn 8, Issue 8, 2008, Pages 1123-1141

  Deonarain, Mahendra P ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Fusion protein; Immunoconjugates; Monoclonal; Radio immunotherapy; Recombinant antibodies

Indexed keywords

ADALIMUMAB; ALEMTUZUMAB; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPROMAB PENDETIDE IN 111; CATUMAXOMAB; CETUXIMAB; CNTO 328; DACLIZUMAB; EPRATUZUMAB; FLUOROURACIL; FOLINIC ACID; GALIXIMAB; GEMCITABINE; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; IRINOTECAN; LUMILIXIMAB; MAPATUMUMAB; MATUZUMAB; MDX 060; OFATUMUMAB; PACLITAXEL; PANITUMUMAB; PERTUZUMAB; RECOMBINANT ANTIBODY; RITUXIMAB; SGN 30; TOSITUMOMAB I 131; TRASTUZUMAB; UNINDEXED DRUG; VOLOCIXIMAB;

ABSENCE OF SIDE EFFECTS; ACUTE GRANULOCYTIC LEUKEMIA; ANTIBODY AFFINITY; B CELL LEUKEMIA; CANCER CHEMOTHERAPY; CANCER THERAPY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; DRUG POTENTIATION; GLYCOSYLATION; HEAD AND NECK CANCER; HODGKIN DISEASE; HUMAN; KIDNEY CANCER; LARGE CELL LYMPHOMA; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; LYMPHOMA; MELANOMA; MOLECULAR DYNAMICS; MONOTHERAPY; NEUROBLASTOMA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PERITONEUM CANCER; PROSTATE CANCER; PROTEIN ANALYSIS; REVIEW; TREATMENT RESPONSE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; GLYCOSYLATION; HUMANS; IMMUNOCONJUGATES; MICE; NEOPLASMS; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION;

EID: 47949132979     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.8.8.1123     Document Type: Review

References (163)

1. Reichert JM, Rosensweig CJ, Faden LB, Dewitz MC. Monoclonal antibody successes in the clinic. Nat Biotechnol 2005;23:1073-8
2. Neuberger MS, Williams GT, Fox RO. Recombinant antibodies possessing novel effector functions. Nature 1984;312:604-8
3. Chaudhary VK, Queen C, Junghans RP, et al. A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin. Nature 1989;339:394-7
4. Ehrlich P. Nobel lectures. In: Physiology or medicine 1901 - 1921. Elsevier Publishing Co., Amsterdam; 1967. p. 304-20
5. Reichert JM, Valge-Archer VE. Development trends for monoclonal antibody cancer therapeutics. Nat Rev Drug Discov 2007;6:349-56
6. United States Food and Drug administration. Available from: http://www.fda.gov
7. Seget S. Innovative and targeted cancer therapies. Available at: http://www. bi-interactive.com/index.aspx?Lang=en&list view= list&MainPage=renderTOC&ReportI D=513. Business Insights report; 2007
8. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibodyof predefined specificity. Nature 1975;256:495-7
9. Tonegawa S. Somatic generation of antibody diversity. Nature 1983;302:575-81
10. Shawler DL, Bartholomew RM, Smith LM, Dillman RO. Human immune response to multiple injections of murine monoclonal IgG. J Immunol 1985;135:1530-5
11. Ober RJ, Radu CG, Ghetie V, Ward ES. Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. Int Immunol 2001;13:1551-9
12. Boulianne GL, Hozumi N, Shulman MJ. Production of functional chimaeric mouse/human antibody. Nature 1984;312:643-6
13. Riechmann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature 1988;332:323-7
14. Coiffier B. Rituximab therapy in malignant lymphoma. Oncogene 2007;26:3603-13
15. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-26
16. Nahta R, Esteva FJ. Trastuzumab: triumphs and tribulations. Oncogene 2007;28:3637-43
17. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;23:2335-42
18. Panares RL, Garcia AA. Bevacizumab in the management of solid tumors. Expert Rev Anticancer Ther 2007;7:433-45
19. Hoogenboom HR. Selecting and screening recombinant antibody libraries. Nat Biotechnol 2005;23:1105-16
20. Lonberg N. Human antibodies from transgenic animals. Nat Biotechnol 2005;23:1117-25
21. Jakobovits A, Amado RG, Yang X, et al. From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice. Nat Biotechnol 2007;25:1134-43
22. Voulgari PV, Drosos AA. Adalimumab for rheumatoid arthritis. Expert Opin Biol Ther 2006;6:1349-60
23. Carter PJ. Potent antibody therapeutics by design. Nat Rev Immunol 2006;6:343-57
24. Smith PL, Ryan M. Identification and validation of cell surface antigens for antibody targeting in oncology. Endocr Relat Cancer 2004; 11:659-87
25. Harari PM. Epidermal growth factor receptor inhibition strategies in oncology. Endocr Relat Cancer 2004; 11:689-708
26. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82
27. Press MF, Slamon DJ, Flom KJ, et al. Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol 2002;20:3095-105
28. Cho HS, Mason K, Ramyar KX, et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 2003;421:756-60
29. Nahta R, Yu D, Hung MC, et al. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 2006;3:269-80
30. Franklin MC, Carey KD, Vajdos FF, et al. Insights into ErbB signaling from the structure of the ErbB2-perruzumab complex. Cancer Cell 2004;5:317-28
31. Lorimer IA. Mutant epidermal growth factor receptors as targets for cancer therapy. Curr Cancer Drug Targets 2002;2:91-102
32. Bonavida B. Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions. Oncogene 2007;26:3629-36
33. Hollingsworth MA, Swanson BJ. Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer 2004;4:45-60
34. Pericleous LM, Richards J, Epenetos AA, et al. Characterisation and internalisation of recombinant humanised HMFG-1 antibodies against MUC1. Br J Cancer 2005;93:1257-66
35. Federation of Clinical Immunology Societies (FOCIS) meeting San Diego, 2007. Available from: http://www.antisoma.com/asm/products/ as 1402/as 1402_breast_cancer01.pdf [Last accessed 9 May 2008]
36. SchultzeJL, Vonderheide RH. From cancer genomics to cancer immunotherapy: toward second-generation tumor antigens. Trends Immunol 2001;22:516-23
37. Folkman J. Angiogenesis. Ann Rev Med 2006;57:1-18
38. Fukumura D, Jain RK. Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize. J Cell Biochem 2007;101:937-49
39. Dvorak HE Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002;20:4368-80
40. Panares RL, Garcia AA. Bevacizumab in the management of solid tumors. Exp Rev Anticancer Ther 2007;7:433-45
41. Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005;23:792-9
42. Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006;3:24-40
43. Wu Y, Zhong Z, Huber J, et al. Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer. Clin Cancer Res 2006;12:6573-84
44. Kuwada SK. Drug evaluation: volociximab, an angiogenesis-inhibiting chimeric monoclonal antibody. Curr Opin Mol Ther 2007;9:92-8
45. Hudis CA. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 2007;357:39-51
46. Nahta R, Yu D, Hung MC, et al. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 2006;3:269-80
47. Izumi Y, Xu L, di Tomaso E, et al. Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature 2002;416:279-80
48. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000;6:443-6
49. Seidman AD, Fornier MN, Esteva FJ, et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 2001;19:2587-95
50. Mendelsohn J, Baselga J. Status of epidermal growth factot teceptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003;21:2787-99
51. Galizia G, Lieto E, De Vita F, et al. Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer. Oncogene 2007;26:3654-60
52. Lenz HJ, Van Cutsem E, Khambata-Ford S, et al. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 2006;24:4914-21
53. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45
54. Yang XD, Jia XC, Corvalan JR, et al. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res 1999;59:1236-43
55. Peters M, Siena S, Humblet Y, et al. A phase 3 multi-center, randomised controlled trial of panitumumab plus best supportive care (BSC) vs BSC alone in patients with metastatic colon cancer. Proceedings of European Society for Medical Oncologists (ESMO); Ann Oncol 2006;17:(Suppl.)ix 114-ix 135
56. Kollmannsberger C, Schittenhelm M, Honecker F, et al. A phase I study of the humanized monoclonal anti-epidermal growth factor receptor. (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC). Ann Oncol 2006;17:1007-13
57. Bonavida B. Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions. Oncogene 2007;26:3629-36
58. Janas E, Priest R, Wilde JI, et al. Rituxan (anti-CD20 antibody)-induced translocation of CD20 into lipid rafts is crucial for calcium influx and apoptosis. Clin Exp Immunol 2005;139:439-46
59. McLaughlin P, Grillo-López AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825-33
60. Leonard JP, Goldenberg DM. Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies. Oncogene 2007;26:3704-13
61. Phillips KE, Herring B, Wilson LA, et al. IL-2Rα-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ra interaction. Cancer Res 2000;60:6977-84
62. O'Mahony D, Morris JC, Casquerillo JA, et al. Phase I/II study of Yttrium-90 labelled humanised anti-Tac (HAT) monoclonal antibody and calcium DPTA in CD25-expressing malignancies. J Nucl Med 2006;47:98
63. Takeda K, Stagg J, Yagita H, et al. Targeting death-inducing receptors in cancer therapy. Oncogene 2007;26:3745-57
64. TolcherAW, Mita M, Meropol NJ, et al. Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. J Clin Oncol 2007;25:1390-5
65. Iannello A, Ahmad A. Role of antibody-dependenT cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies. Cancer Metastasis Rev 2005;24:487-99
66. Alegre ML, Tso JY, Sattar HA, et al. An anti-murine CD3 monoclonal antibody with a low affinity for Fc gamma receptors suppresses transplantation responses while minimizing acute toxicity and immunogenicity. J Immunol 1995;155:1544-55
67. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood 2002;99:754-8
68. Alinari L, Lapalombella R, Andritsos L, et al. Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia. Oncogene 2007;26:3644-53
69. Cartron G, Watier H, Golay J, Solal-Celigny P. From the bench to the bedside: ways to improve rituximab efficacy. Blood 2004;104:2635-42
70. Bowles JA, Wang SY, Link BK, et al. Anti-CD20 monoclonal antibody with enhanced affinity for CD 16 activates NK cells at lower concentrations and more effectively than rituximab. Blood 2006;108:2648-54
71. TangY, Lou J, Alpaugh RK, et al. Regulation of antibody-dependent cellular cytotoxicity by IgG intrinsic and apparent affinity for target antigen. J Immunol 2007;179:2815-23
72. Mone AP, Cheney C, Banks AL, et al. Alemtuzumab induces caspase-independent cell death in human chronic lymphocytic leukemia cells through a lipid raft-dependent mechanism. Leukemia 2006;20:272-9
73. van Meerten T, van Rijn RS, Hol S, et al. Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependenT cellular cytotoxicity. Clin Cancer Res 2006;12:4027-35
74. Di Gaetano N, Cittera E, Nota R, et al. Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol 2003;171:1581-7
75. Glennie MJ, French RR, Cragg MS, Taylor RP. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol 2007;44:3823-37
76. Hale G, Xia MQ, Tighe HP, et al. The CAMPATH-1 antigen (CDw52). Tissue Antigens 1990;35:118-27
77. ElterT, Borchmann P, Schulz H, et al. Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial. J Clin Oncol 2005;23:7024-31
78. Faderl S, Thomas DA, O'Brien S, et al. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood 2003;101:3413-5
79. Guermonprez P, Valladeau J, Zitvogel L, et al. Antigen presentation and T cell stimulation by dendritic cells. Ann Rev Immunol 2002;20:621-67
80. Inman BA, Frigola X, Dong H, Kwon ED. Costimulation, coinhibition and cancer. Curr Cancer Drug Targets 2007;7:15-30
81. Langer LF, Clay TM, Morse MA. Update on anti-CTLA-4 antibodies in clinical trials. Expert Opin Biol Ther 2007;7:1245-56
82. Stebbings R, Findlay L, Edwards C, et al. "Cytokine storm" in the phase I trial of monoclonal antibodyTGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics. J Immunol 2007;179:3325-31
83. Melero I, Hervas-Stubbs S, Glennie M, et al. Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer 2007;7:95-106
84. Thompson S, Stewart R, Smith JA, Self CH. Light activation of anti-CD3 in vivo reduces the growth of an aggressive ovarian carcinoma. ChemMedChem 2007;2:1591-3
85. Pressman D, Korngold L. The in vivo localization of anti-Wagner- osteogenic-sarcoma antibodies. Cancer 1953;6:619-23
86. Goldenberg DM, DeLand F, Kim E, et al. Use of radiolabeled antibodies to carcinoembryonic antigen for the detection and localization of diverse cancers by external photoscanning. N Engl J Med 1978;298:1384-6
87. Sharkey RM, Goldenberg DM. Perspectives on cancer therapy with radiolabeled monoclonal antibodies. J Nucl Med 2005;46(Suppl 1):115S-127S
88. Goldenberg DM, Sharkey RM. Advances in cancer therapy with radiolabeled monoclonal antibodies. QJ Nucl Med Mol Imaging 2006;50:248-64
89. Davies AJ. Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I(131) tositumomab. Oncogene 2007;26:3614-28
90. Sgouros G, Ballangrud AM, Jurcic JG, et al. Pharmacokinetics and dosimetry of an a-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia. J Nucl Med 1999;40:1935-46
91. Goldenberg DM, Sharkey RM. Novel radiolabeled antibody conjugates. Oncogene 2007;26:3734-44
92. Forster GJ, Santos EB, Smith-Jones PM,et al. Pretargeted radioimmunotherapy with a single-chain antibody/streptavidin construct and radiolabeled DOTA-biotin: strategies for reduction of the renal dose. J Nucl Med 2006;47:140-9
93. Pagano L, Fianchi L, Caira M, et al. The role of Gemtuzumab Ozogamicin in the treatment of acute myeloid leukaemia patients. Oncogene 2007;26:3679-90
94. Tolcher AW, Sugarman S, Gelmon KA, et al. Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer. J Clin Oncol 1999;17:478-84
95. Kovtun YV, Audette CA, Ye Y, et al. Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res 2006;66:3214-21
96. Wu AM, Senter PD. Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol 2005;23:1137-46
97. Pastan I, Hassan R, FitzGerald DJ, Kreitman RJ. Immunotoxin treatment of cancer. Ann Rev Med 2007;58:221-37
98. Sievers EL, Appelbaum FR, Spielberger RT, et al. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood 1999;93:3678-84
99. Walter RB, Raden BW, Kamikura DM, et al. Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity. Blood 2005; 105(3): 1295-302
100. Linenberger ML, HongT, Flowers D, et al. Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin. Blood 2001;98:988-94
101. Ma D, HopfCE, Malewicz AD, et al. Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigen. Clin Cancer Res 2006;12:2591-6
102. Erickson HK, Park PU, Widdison WC, et al. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res 2006;66:4426-33
103. Sauter A, Kloft C, Gronau S, et al. Pharmacokinetics, immunogenicity and safety of bivatuzumab mertansine, a novel CD44v6-targeting immunoconjugate, in patients with squamous cell carcinoma of the head and neck. Int J Oncol 2007;30:927-35
104. Pastan I, Hassan R, Fitzgerald DJ, Kreitman RJ. Immunotoxin therapy of cancer. Nat Rev Cancer 2006;6:559-65
105. Kreitman RJ, Wilson WH, Bergeron K, et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukaemia. N Engl J Med 2001;345:241-7
106. Kreitman RJ, Wilson WH, White JD, et al. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol 2000;8:1622-36
107. Kreitman RJ, Squires DR, Stetler-Stevenson M, et al. Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies. J Clin Oncol 2005;23:6719-29
108. Salvatore G, Beers R, Margulies I, et al. Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display. Clin Cancer Res 2002;8:995-1002
109. Rodriguez-Nieto S, Zhivotovsky B. Role of alterations in the apoptotic machinery in sensitivity of cancer cells to treatment. Curr Pharm Des 2006;12:4411-25
110. Lu Y, Li X, Liang K, et al. Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab. Cancer Res 2007;67:8240-7
111. Prewett MC, Hooper AT, Bassi R, et al. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin Cancer Res 2002;8:994-1003
112. Filpula D. Antibody engineering and modification technologies. Biomol Eng 2007;4:201-15
113. Hinton PR, Xiong JM, Johlfs MG, et al. An engineered human IgG 1 antibody with longer serum half-life. J Immunol 2006;176:346-56
114. Umana P, Jean-Mairet J, Moudry R, et al. Engineered glycoforms of an antineuroblastoma IgG 1 with optimized antibody-dependenT cellular cytotoxic activity. Nat Biotechnol 1999;17:176-80
115. Shinkawa T, Nakamura K, Yamane N, et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG 1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 2003;278:3466-73
116. KandaY, YamadaT, Mori K, et al. Comparison of biological activity among nonfucosylated therapeutic IgG 1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types. Glycobiology 2007;17:104-18
117. Suzuki E, Niwa R, Saji S, et al. 1882. A nonfucosylated anti-HER2 antibody augments antibody-dependent cellular cytotoxicity in breast cancer patients. Clin Cancer Res 2007;13:1875-82
118. Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 2006;313:670-3
119. Shields RL, Namenuk AK, Hong K, et al. High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of IgG1 variants with improved binding to the FcγR. J Biol Chem 2001;276:6591-604
120. Lazar GA, Dang W, Karki S, et al. Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci USA 2006;103:4005-10
121. Adams GP, Schier R, McCall AM, et al. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res 2001;61:4750-5
122. Maynard JA, Maassen CB, Leppla SH, et al. Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity. Nat Biotechnol 2002;20:597-601
123. Trikha M, Corringham R, Klein B, Rossi JE Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res 2003;9:4653-65
124. Wu H, Pfarr DS, Tang Y, et al. Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization. J Mol Biol 2005;350:126-44
125. WongJY, Chu DZ, Williams LE, et al. Pilot trial evaluating an 1231-labeled 80-kilodalton engineered anticarcinoembryonic antigen antibody fragment (cT84.66 minibody) in patients with colorectal cancer. Clin Cancer Res 2004;10:5014-21
126. Wright MJ, Deonarain MP. Phage display of chelating recombinant antibody libraries. Mol Immunol 2007;44:2860-9
127. Pini A, Viti F, Santucci A, et al. Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel. J Biol Chem 1998;273:21769-76
128. Edwards BM, Barash SC, Main SH, et al. The remarkable flexibility of the human antibody repertoire; isolation of over one thousand different antibodies to a single protein, BLyS. J Mol Biol 2003;334:103-18
129. Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nat Biotechnol 2005;23:1126-36
130. Begent RH, Verhaar MJ, Chester KA,et al. Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library. Nat Med 1996;2:979-84
131. Beckman RA, Weiner LM, Davis HM. Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumors. Cancer 2007;109:170-9
132. Chapman AP. PEGylated antibodies and antibody fragments for improved therapy: a review. Adv Drug Deliv Rev 2002;54:531-45
133. Constantinou A, Epenetos AA, Hreczuk-Hirst D, et al. Modulation of antibody pharmacokinetics by chemical polysialylation. Bioconj Chem 2008;19:643-50
134. Graumann K, Premstaller A. Manufacturing of recombinant therapeutic proteins in microbial systems. Biotechnol J 2006;1:164-86
135. Argenta and Domantis announce successful study of inhaled domain antibody for chronic obstructive pulmonary disease. Available from: http://www. argentadiscovery.com/news/ press_releases/archive/261005_domantis.html [Last accessed 9 May 2008], and Tomlinson I. IBC Antibody Engineering Conference; December 2007; San Diego
136. Deonarain MP, Epenetos AA. Design, characterization and anti-tumour cytotoxicity of a panel of recombinant, mammalian ribonuclease-based immunotoxins. Br J Cancer 1998;7:537-46
137. Linardou H, Epenetos AA, Deonarain MP. A recombinant cytotoxic chimera based on mammalian deoxyribonuclease-I. Int J Cancer 2000;;86(4):561-9
138. Fischer N, Léger O. Bispecific antibodies: molecules that enable novel therapeutic strategies. Pathobiology 2007;74:3-14
139. Burges A, Wimberger P, Kumper C, et al. Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM × anti-CD3 antibody: a phase I/II study. Clin Cancer Res 2007;13:3899-905
140. Kiewe P, Hasmuller S, Kahlert S, et al. Phase I trial of the trifunctional anti-HER2 × anti-CD3 antibody ertumaxomab in metastatic breast cancer. Clin Cancer Res 2006;12:3085-91
141. Zafir-Lavie I, Michaeli Y, Reiter Y. Novel antibodies as anticancer agents. Oncogene 2007;26:3714-33
142. Du X, Ho M & Pastan I. New immunotoxins targeting CD 123, a stem cell antigen on acute myeloid leukemia cells. J Immunother 1997;30:607-13
143. Gurbaxani B. Mathematical modeling as accounting: predicting the fate of serum proteins and therapeutic monoclonal antibodies. Clin Immunol 2007;122:121-4
144. Rao BM, Lauffenburger DA, Wittrup KD. Integrating cell-level kinetic modeling into the design of engineered protein therapeutics. Nat Biotechnol 2005;23:191-4
145. Lippow SM, Wittrup KD, Tidor B. Computational design of antibody-affinity improvement beyond in vivo maturation. Nat Biotechnol 2007;25:1171-6
146. Mould DR, Sweeney KR. The pharmacokinetics and pharmacodynamics of monoclonal antibodies-mechanistic modeling applied to drug development. Curr Opin Drug Discov Devel 2007;10:84-96
147. Baker MP, Jones TD. Identification and removal of immunogenicity in therapeutic proteins. Curr Opin Drug Discov Devel 2007;10:219-27
148. Mazor Y, Van Blarcom T, Mabry R, et al. Isolation of engineered, full-length antibodies from libraries expressed in Escherichia coli. Nat Biotechnol 2007;25:563-5
149. Sartore-Bianchi A, Moroni M, Veronese S, et al. Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J Clin Oncol 2007;25:3238-45
150. Saltz LB, Lenz HJ, Kindler HL, et al. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin Oncol 2007;25:4557-61
151. Marvin JS, Zhu Z. Bispecific antibodies for dual-modality cancer therapy: killing two signaling cascades with one stone. Curr Opin Drug Discov Devel 2006;9:184-93
152. Lipton A, Steger GG, Figueroa J, et al. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol 2007;25:4431-7
153. Logtenberg T. Antibody cocktails: next-generation biopharmaceuticals with improved potency. Trends Biotechnol 2007;25:390-4
154. Cancer Research UK Clinical Trials database. Available from: http://www. cancerhelp.org.uk/trials/trials/default.asp [Last accessed 9 May 2008]
155. Nomenclature of monoclonal antibodies. United States adopted names. Available from: http://www.ama-assn.org/ ama/pub/category/2956.html[Last accessed 9 May 2008]
156. Mohammed AA, Shergill IS, Vandal M, Gujral SS. ProstaScint and its role in the diagnosis of prostate cancer. Expert Rev Mol Diagn 2007;7:345-9
157. Simon T, Hero B, Faldum A, et al. Infants with stage 4 neuroblastoma: the impact of the chimeric anti-GD2-antibody ch14.18 consolidation therapy. Clin Padiatr 2005;217(3):147-52
158. Divgi CR, Bander NH, Scott AM, et al. Phase I/II radioimmunotherapy trial with iodine-131-labeled mo-noclonal antibody G250 in metastatic renal cell carcinoma. Clin Cancer Res 1998;4:2729-39
159. Leonard J, Friedberg J, Younes A, et al. A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma. Ann Oncol 2007;18:1216-23
160. ByrdJC, O'Brien S, Flinn lW, et al. Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res 2007;13:4448-55
161. Sabbatini P, Dupont J, Aghajanian C, et al. Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Clin Cancer Res 2006;15:5503-10
162. Cerveny CG, Law CL, McCormick RS, et al. Signaling via the anti-CD30 mAb SGN-30 sensitizes Hodgkin's disease cells to conventional chemotherapeutics. Leukemia 2005;19:1648-55
163. Ansell SM, Horwitz SM, Engert A, et al. Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. J Clin Oncol 2007;25:2764-9